---
title: How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction
date: '2024-06-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38848538/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240608181749&v=2.18.0.post9+e462414
source: Blood
description: 'Polycythemia vera (PV) was first described by Vaquez in 1892. This is
  a chronic hematological malignancy which affects both older and young patients.
  Perhaps due to lack of a curative treatment and the perceived toxicities of prior
  therapies our focus in the past was to intensify treatment only for patients at
  higher risk of thrombosis. Recent triggers to challenge this approach include: a
  recognition that low-risk PV is not "no-risk", our ability to better recognize patients
  who would ...'
disable_comments: true
---
Polycythemia vera (PV) was first described by Vaquez in 1892. This is a chronic hematological malignancy which affects both older and young patients. Perhaps due to lack of a curative treatment and the perceived toxicities of prior therapies our focus in the past was to intensify treatment only for patients at higher risk of thrombosis. Recent triggers to challenge this approach include: a recognition that low-risk PV is not "no-risk", our ability to better recognize patients who would ...